Propanc Biopharma, Inc. (Nasdaq: PPCB) filed a provisional patent application in Australia on January 20, 2026 that covers methods for producing the pancreatic proenzymes trypsinogen and chymotrypsinogen. The filing describes an optimized expression system that could enable the manufacture of a fully synthetic version of the company’s lead candidate, PRP, a proenzyme therapy aimed at preventing metastatic cancer.
Continue reading for full analysis...